₹1,057.10
+2.62%NSE close, 16 Nov 2026
+14.66%
Alembic Pharmaceuticals is a small cap company, listed on NSE under the symbol APLLTD. At ₹1,057.10 a share, the market values the whole company at ₹20,779 crore.
In FY26, it reported sales of ₹7,345 crore and a net profit of ₹671 crore, an operating margin of 15.2%. Over the last three years, sales grew 9.1% a year and net profit grew 24.8% a year.
The market values the company at 24.7 times its profit over the last twelve months and 3.50 times its book value; its return on equity is 14.2% and its borrowings are 0.25 times its equity.
Promoters hold 69.87% of the shares. Foreign institutions hold 4.55%, and domestic institutions, mutual funds among them, 15.43%.
Over the past year the share price has risen 15.5%, and it is 1.7% below its 52-week high.
₹ crore. Consolidated figures.
Receives USFDA Final Approval for Binimetinib Tablets, 15 mg and 45 mg.
Transcript
Receives USFDA Final Approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC).
Link of Audio Recording
General Updates: Updated Details of Key Managerial Personnel pursuant to Regulation 30(5) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
| Mar 2026 |
|---|
| Jun 2026 |
|---|
| Sep 2026 |
|---|
| Sales | 1,631 | 1,517 | 1,562 | 1,648 | 1,693 | 1,770 | 1,711 | 1,910 | 1,876 | 1,848 | 2,150 | 2,603 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 1,364 | 1,257 | 1,325 | 1,409 | 1,433 | 1,498 | 1,429 | 1,594 | 1,583 | 1,620 | 1,818 | 2,040 |
| Operating profit | 266 | 260 | 237 | 239 | 260 | 272 | 281 | 316 | 294 | 228 | 332 | 563 |
| Operating margin | 16.3% | 17.1% | 15.2% | 14.5% | 15.4% | 15.4% | 16.4% | 16.5% | 15.6% | 12.3% | 15.4% | 21.6% |
| Other income | 2.9 | 3.6 | 2.1 | 16.8 | 9.5 | 14.2 | 6.5 | 6.9 | 15.5 | 25.5 | 14.9 | 15.1 |
| Interest | 15.2 | 10.9 | 13.2 | 18.8 | 22.3 | 24.5 | 23.5 | 24.2 | 23.3 | 22.6 | 27.6 | 38.3 |
| Depreciation | 69.5 | 69.5 | 69.0 | 70.5 | 70.1 | 69.0 | 73.8 | 76.1 | 80.1 | 88.6 | 97.7 | 101 |
| Profit before tax | 185 | 183 | 157 | 180 | 177 | 193 | 191 | 222 | 163 | 118 | 221 | 439 |
| Tax | 4.1 | 4.6 | 22.5 | 27.3 | 40.1 | 35.3 | 36.5 | 40.0 | 29.6 | −82.9 | 49.5 | 104 |
| Net profit | 180 | 178 | 135 | 153 | 138 | 157 | 154 | 185 | 133 | 202 | 173 | 335 |
| EPS (₹) | 9.18 | 9.07 | 6.85 | 7.79 | 7.01 | 7.98 | 7.85 | 9.40 | 6.76 | 10.31 | 8.80 | 17.05 |
₹ crore, financial years to March.
| Line | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Sales | 3,935 | 4,606 | 5,393 | 5,306 | 5,653 | 6,229 | 6,672 | 7,345 |
| Expenses | 3,061 | 3,383 | 3,836 | 4,432 | 4,944 | 5,295 | 5,664 | 6,226 |
| Operating profit | 874 | 1,223 | 1,558 | 874 | 708 | 933 | 1,008 | 1,118 |
| Operating margin | 22.2% | 26.6% | 28.9% | 16.5% | 12.5% | 15.0% | 15.1% | 15.2% |
| Other income | 9.4 | 4.9 | 10.0 | 50.5 | 2.7 | 28.3 | 42.6 | 54.4 |
| Interest | 18.4 | 27.2 | 16.0 | 17.7 | 50.2 | 56.2 | 78.8 | 93.6 |
| Depreciation | 115 | 157 | 183 | 287 | 275 | 273 | 279 | 319 |
| Profit before tax | 749 | 1,000 | 1,368 | 620 | 386 | 633 | 706 | 694 |
| Tax | 157 | 199 | 253 | 104 | 12.6 | 16.0 | 125 | 23.1 |
| Net profit | −1.1 | 829 | 1,178 | 546 | 345 | 616 | 583 | 671 |
| EPS (₹) | 31.00 | 43.97 | 60.81 | 27.76 | 17.39 | 31.34 | 29.68 | 34.33 |
₹ crore, at each year's end and the latest half year.
| Line | FY23 | FY24 | FY25 | FY26 | Sep 2026 |
|---|---|---|---|---|---|
| Shareholders’ equity | 4,370 | 4,818 | 5,191 | 5,675 | 5,944 |
| Borrowings | 636 | 430 | 1,196 | 1,361 | 1,490 |
| Total liabilities | 1,812 | 1,627 | 2,583 | 3,094 | 3,594 |
| Fixed assets | 2,398 | 2,547 | 2,524 | 2,844 | 2,914 |
| Investments | 71.2 | 68.6 | 101 | 113 | 116 |
| Cash and equivalents | 75.5 | 120 | 83.5 | 196 | 254 |
| Total assets | 6,183 | 6,446 | 7,773 | 8,763 | 9,531 |
₹ crore, by financial year, and the latest half year.
| Line | FY22 | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|---|
| From operations | 552 | 88.0 | 783 | 571 |
| From investing | −372 | −568 | −506 | −328 |
| From financing | −217 | 444 | −164 | −185 |
| Spent on fixed assets | −426 | −564 | −435 | −169 |
| Free cash flow | 127 | −476 | 348 | 402 |
Margins, returns, debt, tax and cash.
| Line | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Net margin | -0.0% | 18.0% | 21.8% | 10.3% | 6.1% | 9.9% | 8.7% | 9.1% |
| Operating margin | 22.2% | 26.6% | 28.9% | 16.5% | 12.5% | 15.0% | 15.1% | 15.2% |
| Return on equity | – | – | – | – | 7.9% | 12.8% | 11.2% | 11.8% |
| Return on capital employed | – | – | – | – | 8.7% | 13.1% | 12.3% | 11.2% |
| Return on assets | – | – | – | – | 5.6% | 9.6% | 7.5% | 7.7% |
| Debt to equity | – | – | – | – | 0.15 | 0.09 | 0.23 | 0.24 |
| Interest coverage | 41.70 | 37.80 | 86.40 | 36.00 | 8.70 | 12.30 | 10.00 | 8.40 |
| Debt to assets | – | – | – | – | 0.10 | 0.07 | 0.15 | 0.16 |
| Current ratio | – | – | – | – | 1.78 | 2.12 | 1.69 | 1.75 |
| Quick ratio | – | – | – | – | 0.88 | 0.99 | 0.75 | 0.78 |
| Cash ratio | – | – | – | – | 0.05 | 0.08 | 0.03 | 0.08 |
| Asset turnover | – | – | – | – | 0.91 | 0.97 | 0.86 | 0.84 |
| Fixed asset turnover | – | – | – | – | 2.36 | 2.45 | 2.64 | 2.58 |
| Inventory turnover | – | – | – | – | – | 1.00 | 0.80 | 0.80 |
| Receivables turnover | – | – | – | – | 5.40 | 6.10 | 4.80 | 5.00 |
| Gross margin | – | – | – | – | – | 72.5% | 73.1% | 73.0% |
| Cash from operations to profit | – | – | – | 101.0% | – | – | 15.0% | 117.0% |
| Effective tax rate | 20.9% | 19.9% | 18.5% | 16.8% | 3.3% | 2.5% | 17.7% | 3.3% |
Please find attached Press Release
Press Release on the Unaudited Financial Results for the quarter and half year ended 30th September, 2026
Outcome of Board Meeting held on November 04, 2026.
The financial results for the period ended September 30, 2026.
Updated link for the Post Results Conference Call
Re-schedule of meet.
Receives USFDA Final Approval for Venetoclax Tablets, 10 mg, 50 mg and 100 mg.
Receives USFDA Final Approval for Valganciclovir for Oral Solution, 50 mg/mL.